ClinicalTrials.gg
CompletedNCT01184456Updated Jan 13, 2021Results posted

A Controlled Trial to Evaluate the Effects of GanedenBC30 on the Immune System

A Phase 2 interventional study of GanedenBC30, GBI-30, PTA-6086 and Placebo in HIV Infection and Gastrointestinal Symptoms, sponsored by AIDS Healthcare Foundation. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-13.

Sponsored by AIDS Healthcare Foundation · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,803 studies in HIV Infections with a site in United States — 84 open to participants now, 141 under way, 11 of them phase 3. HIV Infections · United States.

Enrollment
1,723rd of 2,151
24 · median 60
Started
2010
with 81 others
Phase 2
479 of 2,803
8 open now
Registered
2,164th of 2,803
by date

Among the 2,803 studies in HIV Infections with a site in United States, this one is the 1,723rd largest by enrollment of the 2,151 interventional ones that give a count, is one of 82 that started in 2010, is one of 479 in phase 2, and was the 2,164th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

84 of the 2,803 studies in HIV Infections with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,803 studies in HIV Infections with a site in United States, or all of them as a file.
02

Study summary

Improvement in the rate of bacterial translocation may lead to a decrease in a chronic inflammatory response thereby decreasing CD4 destruction and HIV proliferation.

By the addition of probiotics we hope to show a reduction in LPS leading to a decrease in chronic inflammation and therefore an improvement in immune markers.

03

Conditions studied

  • HIV Infection
  • Gastrointestinal Symptoms

Keywords

  • AIDS
  • Acquired Immunodeficiency Syndrome
  • HIV
  • Human Immunodeficiency Virus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is male or non-pregnant, non-lactating female.
  • Adults 18 years or older.
  • Is able to provide written, to participate in the study.
  • Serological documentation of infection at any time prior to study entry and is clinically stable.
  • Stable greater than or equal to 250 cells/cubic mm for six months prior to study entry (+/- 50 cells/cubic mm).
  • HIV-1 RNA ≤50 copies/mL for six months prior to study entry.
  • performance status - 60%.
  • Adequate laboratory parameters within the last 30 days:

    1. >1000 cells/cubic mm
    2. >9.0 g/dL
    3. >75,000/cubic mm
    4. creatinine \<1.5 x
    5. /SGPT \<3.0 x upper limit of normal
    6. \<2.0 mg/dL
  • Patients with documented GI symptoms to include but are not limited to: flatulence, diarrhea, bloating, gastroesophageal reflux disease, nausea, and constipation.
  • If females are of , they must be practicing an effective method of and agree to use birth control while on protocol and for 1 month after completion of study. Women of Child Bearing Potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to start of study medication. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not. [defined as amenorrhea for 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level > 35 mIU/mL]. Even women who are using oral, implanted or, injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential.
  • Must agree to practice protected sexual activity (via barrier method) during course of the study.
  • In the opinion of the investigator, is willing and able to comply with the study requirements.

Exclusion criteria

Exclusion Criteria:

  • Active opportunistic infection, which is progressive, or imminently disabling or life threatening, in the judgment of the Principal Investigator with exception of Kaposi Sarcoma.
  • Cytotoxic chemotherapy, interferon treatment, or radiation therapy within the preceding 3 weeks (subjects who have received intralesional chemotherapy will not be excluded, however).
  • Any antibiotic therapy within 30 days of enrollment
  • Any probiotic formulation within 30 days of enrollment
  • Any immunization within 30 days of enrollment
  • Known history of allergic reactions to any of the products or their ingredients.
  • Chronic treatment with drugs, including , except for the treatment of adrenal insufficiency. Topical steroids are permitted.
  • History of or known current malabsorption syndrome.
  • Any grade 3 or 4 lab abnormalities as defined by a standardized grading scheme based on the DAIDS table (see Appendix B) with the following exceptions:
  • Pre-existing diabetes with glucose toxicity elevations ≥ grade 3
  • Triglyceride or total cholesterol elevations ≥ grade 3
  • Clinical or laboratory evidence of liver impairment/ dysfunction, disease or cirrhosis.
  • \< 6 months in the opinion of the investigator.
  • Active substance abuse or significant psychiatric illness that in the opinion of the investigator might interfere with study compliance.
  • Female subject of not using effective non-hormonal methods or not willing to continue practicing these birth control methods from screening until the last trial related activity.
  • Subject is pregnant or lactating.
  • Any condition that in the Principal Investigator's opinion may render the subject unable to complete the study or which may pose significant risk to the subject.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    GanedenBC30, GBI-30, PTA-6086

    Dietary Supplement: GanedenBC30, GBI-30, PTA-6086

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Dietary supplementHeyndrickxia coagulansStudies of Heyndrickxia coagulansHeyndrickxia coagulans pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1 capsule per day containing 2 billion CFU of GanedenBC30, GBI-30, PTA-6086 for 90 days.

    Also known as: Bacillus coagulans, Probiotics

  • DrugPlacebo

    1 capsule per day for 90 days.

06

What researchers measure

Primary outcomes

  1. Effects of Daily Consumption of GanedenBC30 on Immune Function and Gastro-intestinal Issues

    The primary endpoint measurement of safety is measured based on the number of adverse events reported relative to the expected number adverse events prior to the start of the study based on a risk analysis. The primary endpoint measurement of immune function is measured based on biological markers including CRP, IL-8 and TNF-alpha between the two groups. The primary endpoint measurement of gastro-intestinal issues is measured based on the number of reported symptoms relative to the expected number of gastro-intestinal issues prior to the start of the study based on a risk analysis.

    Time frame: 30, 60, and 90 days.

07

Results

Posted Sep 11, 2019

Participant flow

Participant flow — Overall Study
MilestoneGanedenBC30, GBI-30, PTA-6086Placebo
Started00
Completed00
Not completed00

Outcome measures

PrimaryEffects of Daily Consumption of GanedenBC30 on Immune Function and Gastro-intestinal Issues

The primary endpoint measurement of safety is measured based on the number of adverse events reported relative to the expected number adverse events prior to the start of the study based on a risk analysis. The primary endpoint measurement of immune function is measured based on biological markers including CRP, IL-8 and TNF-alpha between the two groups. The primary endpoint measurement of gastro-intestinal issues is measured based on the number of reported symptoms relative to the expected number of gastro-intestinal issues prior to the start of the study based on a risk analysis.

Time frame:
30, 60, and 90 days.

No measurements were reported for this outcome.

Adverse events

Collected over PI has left AIDS Healthcare Foundation, all efforts to locate the data have been exhausted and no data is available.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GanedenBC30, GBI-30, PTA-6086———
Placebo———

Baseline characteristics

PI has left AIDS Healthcare Foundation, all efforts to locate the data have been exhausted and no data is available.

Age, Categorical
Age, CategoricalGanedenBC30, GBI-30, PTA-6086PlaceboTotal
<=18 years———
Between 18 and 65 years———
>=65 years———
Age, Continuous
Age, ContinuousGanedenBC30, GBI-30, PTA-6086PlaceboTotal
Sex: Female, Male
Sex: Female, MaleGanedenBC30, GBI-30, PTA-6086PlaceboTotal
Female———
Male———
Region of Enrollment
Region of Enrollment(participants)GanedenBC30, GBI-30, PTA-6086PlaceboTotal
08

Study locations

1 site
  • AHF Research Center
    Beverly Hills, California 90211, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2019, 7 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2010
First posted
Aug 19, 2010
Start
Aug 2010
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results first posted
Sep 11, 2019
Last update
Jan 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01184456
Lead sponsor
AIDS Healthcare Foundation
Collaborators
Ganeden Biotech, Inc.
Responsible party
Sponsor
First posted
Aug 19, 2010
Start date
Aug 2010
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Sep 11, 2019
Last update
Jan 13, 2021

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Heyndrickxia coagulans

Start the discussion